- Home
- ACIC vs PCRX Comparison
ACIC vs PCRX Comparison
Compare ACIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | PCRX |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.2M | 1.0B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ACIC | PCRX |
|---|---|---|
| Price | $12.80 | $26.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.86 |
| AVG Volume (30 Days) | 124.8K | ★ 832.1K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | 0.47 |
| Revenue | $328,331,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $5.03 | $6.24 |
| Revenue Next Year | $2.40 | $9.53 |
| P/E Ratio | ★ $7.29 | $54.91 |
| Revenue Growth | ★ 22.22 | 3.14 |
| 52 Week Low | $9.97 | $18.17 |
| 52 Week High | $13.64 | $27.64 |
Technical Indicators
Market Signals| Indicator | ACIC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 57.95 |
| Support Level | $12.51 | $25.56 |
| Resistance Level | $13.06 | $26.70 |
| Average True Range (ATR) | 0.27 | 0.92 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 56.77 | 42.36 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.